Incretin-based therapies such as Ozempic® (a GLP-1 receptor agonist) and Mounjaro® (a dual GIP/GLP-1 agonist) are among the most effective treatments for type 2 diabetes. Unlike older medications that target a single pathway, these therapies improve blood sugar control through multiple complementary mechanisms that address key drivers of diabetes.
How GLP-1 Works in the Body
GLP-1 is a natural hormone released by the gut after eating. GLP-1 medications mimic this hormone and help regulate blood sugar in several key ways:
- Increase insulin release "when blood sugar is high" , reducing the risk of hypoglycemia.
- Suppress glucagon , a hormone that raises blood sugar.
- Slow gastric emptying , leading to smaller post-meal glucose spikes
- Reduce appetite , supporting weight loss and improved insulin sensitivity
Impact on Blood Sugar and A1C
Because GLP-1 medications act on both fasting and post-meal glucose levels, many patients experience:
- Significant A1C reduction (often 1–2%)
- More stable blood sugar throughout the day
- Fewer glucose spikes after meals
This makes GLP-1 therapy especially helpful for patients who struggle with fluctuating or poorly controlled diabetes.
Additional Metabolic Benefits
Beyond glucose control, GLP-1 medications often lead to:
- Weight loss
- Improved insulin resistance
- Better blood pressure and cholesterol profiles
- Reduced cardiovascular risk in patients with type 2 diabetes
Final Takeaway
GLP-1 medications improve diabetes control by addressing both blood sugar regulation and the underlying metabolic drivers of disease . When used under medical supervision, they offer a safe and effective option for patients who need better glycemic control and long-term metabolic improvement.
GLP1 Agonists are contraindicated in patients with medullary thyroid carcinoma, History of Multiple endocrine neoplasia syndrome Type 2 (MEN2)